Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar:6:100096.
doi: 10.1016/j.tru.2021.100096. Epub 2022 Jan 3.

Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxis

Birgitte Tholin  1   2   3 , Hilde Fiskvik  4 , Anders Tveita  5 , Galina Tsykonova  1   3   6 , Helene Opperud  1 , Kari Busterud  7 , Clarisse Mpinganzima  8 , Lamya Garabet  9 , Jamal Ahmed  1 , Knut Stavem  3   10   11 , Waleed Ghanima  1   12
Affiliations

Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxis

Birgitte Tholin et al. Thromb Update. 2022 Mar.

Abstract

Introduction: The incidence of thromboembolism during COVID-19 and the use of thromboprophylaxis vary greatly between studies. Only a few studies have investigated the rate of thromboembolism post-discharge. This study determined the 90-day incidence of venous and arterial thromboembolic complications, risk factors for venous thromboembolic events and characterized the use of thromboprophylaxis during and after hospitalization.

Materials and methods: We retrospectively reviewed medical records for adult patients hospitalized for >24 h for COVID-19 before May 15, 2020, in ten Norwegian hospitals. We extracted data on demographics, thromboembolic complications, thromboembolic risk factors, and the use of thromboprophylaxis. Cox proportional hazards regression was used to determine risk factors for VTE.

Results: 550 patients were included. The 90-day incidence of arterial and venous thromboembolism in hospitalized patients was 6.9% (95% CI: 5.1-9.3) overall and 13.8% in the ICU. Male sex (hazard ratio (HR) 7.44, 95% CI 1.73-32.02, p = 0.007) and previous VTE (HR 6.11, 95% CI: 1.74-21.39, p = 0.005) were associated with risk of VTE in multivariable analysis. Thromboprophylaxis was started in 334 patients (61%) with a median duration of 7 days (25th-75th percentile 3-13); in the VTE population 10/23 (43%) started thromboprophylaxis prior to diagnosis. After discharge 20/223 patients received extended thromboprophylaxis and 2/223 (0.7%, 95% CI: 0.3-1.9) had a thromboembolism.

Conclusions: The 90-day incidence of thromboembolism in COVID-19 patients was 7%, but <1% after discharge. Risk factors were male sex and previous VTE. Most patients received thromboprophylaxis during hospitalization, but only <10% after discharge.

Keywords: COVID-19; Risk factors; Thromboembolism; Thromboprophylaxis.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Waleed Ghanima reports fees for participation in Advisory board from Amgen, Novartis, Pfizer, Principia Biopharma Inc- a Sanofi Company, Sanofi, SOBI, Griffols, UCB, Argenx. Lecture honoraria from Amgen, Novartis, Pfizer, Bristol Myers Squibb, SOBI, Griffols, Sanofi. Research grants from Bayer, and BMS/Pfizer. Galina Tsykunova reports lecture honoraria from Amgen, Janssen, Ablynx, Sanofi and Sobi. Research grants from Janssen.

Figures

Fig. 1
Fig. 1
Kaplan Meier plot of the cumulative incidence of venous thromboembolic events (VTE) during and after hospitalization for males and females.
See this image and copyright information in PMC

References

    1. Middeldorp S., Coppens M., van Haaps T.F., Foppen M., Vlaar A.P., Müller M.C.A., et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J. Thromb. Haemostasis. 2020;18(8):1995–2002. - PMC - PubMed
    1. Klok F.A., Kruip M., van der Meer N.J.M., Arbous M.S., Gommers D., Kant K.M., et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb. Res. 2020;191:148–150. - PMC - PubMed
    1. Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemostasis. 2020;18(6):1421–1424. - PMC - PubMed
    1. Klok F.A., Kruip M., van der Meer N.J.M., Arbous M.S., Gommers D., Kant K.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020;191:145–147. - PMC - PubMed
    1. Helms J., Tacquard C., Severac F., Leonard-Lorant I., Ohana M., Delabranche X., et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–1098. - PMC - PubMed